Evidence map›Paper›PMID 41821894›Full record

ArticleFrontiers in oncology2026

Identification of KRAS mutation in rectal cancer based on a 2.5D deep learning model.

Chengmeng Zhang, Jinge Li, Peng Chen, Yanyan Zhou, Jian Shen, Guanfeng Chen

Abstract read
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chengmeng ZhangRadiology Department of Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Huzhou, China.
Jinge LiMedical School of Huzhou University, Huzhou, China.
Peng ChenRadiology Department of Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Huzhou, China.
Yanyan ZhouRadiology Department of Changxing County Traditional Chinese Medicine Hospital, Huzhou, China.
Jian ShenRadiology Department of Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Huzhou, China.
Guanfeng ChenRadiology Department of Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To explore the utility of a 2.5D deep transfer learning (DTL) model for distinguishing between Kirsten rat sarcoma viral oncogene (KRAS) mutant and wild-type phenotypes in patients with rectal cancer (RC). Methods: We retrospectively analyzed 138 patients with pathologically confirmed RC who underwent next-generation sequencing to detect KRAS mutations. Among these, 43 KRAS mutant and 95 wild-type cases were enrolled and divided randomly into a training set (30 mutant, 66 wild-type) and a validation set (13 mutant, 29 wild-type) in a 7:3 ratio. Tumor regions of interest (ROIs) were delineated manually slice-by-slice in thin-section arterial-phase computed tomography images. DTL and radiomic features were extracted from ROIs using 2.5D deep learning and traditional radiomic approaches, respectively. After feature-dimensionality reduction and selection, six machine learning models were employed to construct radiomic models and 2.5D deep learning models. The diagnostic performance of each model was evaluated using the area under the receiver operating characteristic curve (AUC). Results: After feature selection, 10 radiomic features and 17 DTL features were included for model construction. The AUCs for the radiomic models ranged from 0.808-0.988 in the training set and 0.521-0.672 in the validation set, with the XGBoost classifier achieving the optimal performance (AUC = 0.672) in the validation set. The AUCs for the 2.5D deep learning models ranged from 0.950-1.000 in the training set and 0.788-0.913 in the validation set, with the support vector machine classifier demonstrating the best diagnostic efficacy (AUC = 0.913) in the validation set. Conclusion: A 2.5D deep learning model can effectively distinguish between KRAS mutant and KRAS wild-type RC, outperforming traditional radiomic models. It provides a novel non-invasive approach for the preoperative assessment of KRAS mutation status.

Indexed as

deep transfer learninggene mutationradiomicsrectal cancerX-ray computed tomography

Identifiers

PMID41821894
PMCPMC12975492

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.